Table 1.

General characteristics of included meta-analyses^a

Reference	Year	Country	Studies	Participants	Sex (F/M)	Cancer Types	Interventions	CRF Assessment
Brown et al. [10]	2011	United States	44	3254	F/M	breast, colorectal, leukemia, lymphoma, prostate, mixed	AE and/or ST	BFI, EORTC-QLQ C30, FACT, FACT-An, FACT-B, FACT-F, FACT-G, LAS, PFS, POMS, SAS, SCFS, SF-36, 0–9 scale
Carayol et al. [11]	2013	France	11	–	F	breast	AE and/or ST	BFI, FACT-F, MFI, PFS, SF-36(Vitality)
Carayol et al. [12]	2015	France	21	2181	F	breast	AE and/or ST	SF-36(Vitality)
Cramer et al. [13]	2014	Germany	3	157	F/M	colorectal	AE and/or ST	FACT-F
Duijts et al. [16]	2011	Netherlands	11	1244	F	breast	AE and/or ST	FACT-F, FS, LAS-F, POMS, PFS, SCFS
Fong et al. [17]	2012	China	6	758	F/M	breast, colon, colorectal, endometrial, gastric, gynecological, lung, lymphoma, testicular	AE and/or ST	EORTC-F, FACT-F, PFS
Jacobsen et al. [18]	2007	United States	12	833	F/M	breast, colon, colorectal, multiple myeloma, prostate, mixed	AE and/or ST	–
Kangas et al. [19]	2008	United States	16	1001	F/M	breast, colorectal, gastrointestinal, lung, myeloma, prostate, mixed	AE and/or ST	BFI, EORTC QLQ C30, FACIT-F, FACT-B, FACT-C, FACT-P/F, FACT-B/G, LAS-F, LASA fatigue/energy/anxiety/depression, PFS, PFS-R, POMS, POMS-F, POMS-SV, SAS-F, SF-36
Meneses-Echavez et al. [24]	2015	Colombia	9	–	F/M	breast, prostate, mixed	AE and/or ST	EORTC QLQ C30, FACT-B, FACT-F, FACT-G, FACT-P, PFS, SCFS
Meneses-Echavez et al. [25]	2015	Colombia	9	1016	F	breast	AE and/or ST	EORTC QLQ C30, FACT-B, FACT-F, FACT-G, FACT-P, PFS, SCFS
Meneses-Echavez et al. [26]	2015	Colombia	11	1427	F/M	breast, lymphoma, prostate	AE and/or ST	EORTC QLQ C30, FACT-B, FACT-F, FACT-G, FACT-P, PFS, SCFS
Tian et al. [31]	2016	China	26	2830	F/M	breast, colorectal, gynecologic, hematological, nasopharyngeal prostate, other	AE	BFI, FACT-F, LASA, PFS, PFS-R, POMS
Van Haren et al. [33]	2013	Netherlands	2	115	–	cancer patients undergoing hematopoietic stem cell transplantation	AE and/or ST	FACT-An, MFI, POMS-F
Van Vulpen et al. [34]	2016	Netherlands	3	–	F/M	breast	AE and/or ST	FAQ, MFI-20
Velthuis et al. [35]	2010	Netherlands	7	674	F/M	acute myelogenous leukemia, breast, multiple myeloma, prostate	AE and/or ST	BFI, FACIT-F, FACT-An, FACT-F, PFS, PFS-R, POMS, SAS
Zou et al. [36]	2014	China	6	371	–	breast	AE	FACIT-F, PFS-R

Notes: ^aData representative of studies in which CRF was assessed; −-, data not available; CRF Cancer-Related Fatigue, F is Female and M is Male, AE aerobic exercise, ST Strength training, BFI Brief Fatigue Index, EORTC-F European Organization for Research and Treatment of Cancer – Fatigue, EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue scale, FACT Functional Assessment of Cancer Therapy, FACT-An Functional Assessment of Cancer Therapy – Anemia, FACT-B Functional Assessment of Cancer Therapy – Breast Cancer, FACT-B/G Functional Assessment of Cancer Therapy – Breast Cancer/General, FACT-C Functional Assessment of Cancer Therapy – Colon Cancer, FACT-F Functional Assessment of Cancer Therapy – Fatigue, FACT-G Functional Assessment of Cancer Therapy – General, FACT-P/F Functional Assessment of Cancer Therapy – Prostate Cancer and Fatigue, FAS Fatigue Assessment Questionnaire, LAS Linear Analog Scale, LASA Linear Analog Self-Assessment, LASA-F Linear Analog Self-Assessment-Fatigue, MFI Multidimensional Fatigue Inventory, PFS Piper Fatigue Scale, PFS-R Piper Fatigue Scale-Revised, POMS Profile of Moods States, POMS-SV Profile of Mood States, Short-Version, SAS Symptom Assessment Scale, SAS-F Symptom Assessment Scale-Fatigue, SCFS Schwartz Cancer Fatigue Scale, SF-36 Medical Outcomes Study, Short-Form 36